Month: September 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from Havila Kystruten AS (“Havila Kystruten” or the “Company”) on 8 September 2023 regarding the commencement of the subscription period (the “Subscription Period”) in the subsequent offering (the “Subsequent Offering”) of up to 60,000,000 new shares in the Company (the “Offer Shares”) at a subscription price of NOK 1.00 per share (the “Offer Price”). Reference is also made to the...

Almere, The Netherlands September 26, 2023, 7:45 a.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today hosts its 2023 Investor Day in London. During this event ASM’s management will provide an update on our business and financials, and discuss how new technology developments will drive expected market expansion and new growth opportunities for ASM. We will also explain in more detail our initiatives to accelerate Sustainability. Highlights include:Revenue target for 2025 increased to €3.0-€3.6 billion1, up from the previous 2021 Investor Day target of €2.8-€3.4 billion. Further growth in revenue to €4.0-€5.0 billion by 2027 (2022-2027 CAGR of 11%-16%). Gross margin of 46%-50% and operating margin of 26%-31% reiterated for 2023-2025, and also targeted for 2026-20272, with upward trend in operating margin expected in outer...

Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from extensive analytical characterization demonstrating similarity of biosimilar with reference biologic, in addition to Phase I and confirmatory Phase III studies.Sandoz is committed to accelerate access to potentially life-changing treatments, while generating savings for healthcare systems and patients around the worldBasel, September 26, 2023 — Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko® (natalizumab), developed by Polpharma Biologics. The authorization covers treatment as a single disease-modifying...

Ghent, BELGIUM , Sept. 26, 2023 (GLOBE NEWSWIRE) — Press release Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for crop and food protection, today announces the participation of the company in a variety of upcoming events. Biotalys welcomes the opportunity to engage with the scientific community, industry, and investors during these events to share the company’s ongoing development of its pipeline and technology platform. World Agri-Tech Innovation SummitSeptember 26-27, 2023London, UKPatrice Sellès, CEO of Biotalys, will participate in a panel discussion. POLITICO The Future of Food and Agriculture SummitSeptember 28, 2023Paris, France Investor Access (event in French) October 9-10, 2023Paris, France European Congress of EntomologyOctober 16-20, 2023Heraklion,...

Press Release  Nokia launches Network as Code platform to accelerate network programmability and monetizationNokia Network as Code platform and developer portal provides simplified network capabilities to developers as software code that can be easily integrated into applications Network as Code platform reflects a strategic focus of Nokia to drive new business models and to unlock the potential that networks can deliver from the perspective of  innovation, sustainability, collaboration, and productivity Nokia and DISH Wireless have agreed to a memorandum of understanding to partner on an ecosystem project using Nokia’s Network as Code platform and the DISH 5G cloud-native network26 September 2023 Espoo, Finland – Nokia today introduced its Network as Code platform and developer portal that enables application developers and communication...

PRESS RELEASE:INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST AGREEMENT REGARDING RECAPITALIZATION OF OPERATING SUBSIDIARIES BY SECURED CREDITORS AND WIND DOWN OF LISTED HOLDING COMPANYThe Company’s Secured Creditors (being its First Lien Creditors and Bondholders, as defined below) will take ownership of the Biocartis operating subsidiaries through enforcement and inject EUR 40 million of new equity capital to fund the business to EBITDA break-even by the end of 2024 Under the ownership of the Secured Creditors, the business will have a right-sized balance sheet with EUR 132 million of deleveraging from today Transaction should be completed by end of 2023 and is not expected to impact Biocartis’s customers, suppliers, partners or employees Shareholders of Biocartis Group NV will receive no distribution...

Hydro’s third quarter results 2023 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on Tuesday, October 24, 2023. The quarterly report and presentation will be available on hydro.com at the same time.  President and CEO Hilde Merete Aasheim and Executive Vice President and CFO Pål Kildemo will host a webcast in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no presentation or press conference at our corporate headquarters.  To join the webcast and ask questions, register your details in the webcast page. Once registered, you will receive a separate email confirming your registration. The webcast is powered by Livestorm. We advise that you investigate in advance if your company has any restrictions using this platform. Investor contact:Martine...

Mithra Financial Results for First-Half 2023Good progress on strategy to strengthen balance sheet and refocus on innovative R&D Revenues EUR 7.0 million, driven by Estelle® and Myring® sales U.S. Estelle® (Nextstellis®) H1 dispensed cycles surged 80% over H2 2022 EU Estelle® (DROVELIS®) revenues hit EUR 1.5 million; launched in new EU and Latam countries Financing secured with EUR 20 million private placement in August 2023 and access to EUR 12.5 million loan facility in June 2023 Positive top-line results from Donesta® Phase 3 program and confirmation of safety profile support application for U.S. marketing authorization by year-end Signed binding term sheet for Canadian licensing deal for Donesta® with Searchlight Pharma, worth up to EUR 17.05 million plus royalties Cash position EUR 23.7 million at end June 2023Liege, Belgium,...

PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND RECAPITALIZATION Company will host a conference call with live webcast presentation today at 14:30 CEST / 13:30 BST (UK) / 08:30 EDT (US) to discuss H1 2023 resultsSolid performance with 22% growth of oncology cartridge revenue, a 40% gross margin on product sales and a 20% improvement in EBITDA to EUR -14.5m Operational reorganization and cost reduction program nearing completion aimed at reaching operating break-even result by the end of 2024 Comprehensive recapitalization and balance sheet restructuring plan by secured creditors announced and expected wind down of listed holding entityMechelen, Belgium, 26 September 2023 – Biocartis Group NV (the...

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. To participate in the conference call, please register in advance here. To access the live and archived webcast, please visit Immunovant’s website at https://www.immunovant.com/investors/news-events. The archived webcast will be available for a limited time on the Company’s website. About Immunovant, Inc.Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases....